130 related articles for article (PubMed ID: 11705455)
1. Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone.
Pines M; Domb A; Ohana M; Inbar J; Genina O; Alexiev R; Nagler A
Biochem Pharmacol; 2001 Nov; 62(9):1221-7. PubMed ID: 11705455
[TBL] [Abstract][Full Text] [Related]
2. Topical treatment of cutaneous chronic graft versus host disease with halofuginone: a novel inhibitor of collagen type I synthesis.
Nagler A; Pines M
Transplantation; 1999 Dec; 68(11):1806-9. PubMed ID: 10609960
[TBL] [Abstract][Full Text] [Related]
3. Halofuginone to treat fibrosis in chronic graft-versus-host disease and scleroderma.
Pines M; Snyder D; Yarkoni S; Nagler A
Biol Blood Marrow Transplant; 2003 Jul; 9(7):417-25. PubMed ID: 12869955
[TBL] [Abstract][Full Text] [Related]
4. Effect of halofuginone on the development of tight skin (TSK) syndrome.
McGaha T; Kodera T; Phelps R; Spiera H; Pines M; Bona C
Autoimmunity; 2002 Jul; 35(4):277-82. PubMed ID: 12482197
[TBL] [Abstract][Full Text] [Related]
5. Halofuginone: a novel antifibrotic therapy.
Pines M; Nagler A
Gen Pharmacol; 1998 Apr; 30(4):445-50. PubMed ID: 9522159
[TBL] [Abstract][Full Text] [Related]
6. Halofuginone--an inhibitor of collagen type I synthesis--prevents postoperative formation of abdominal adhesions.
Nagler A; Rivkind AI; Raphael J; Levi-Schaffer F; Genina O; Lavelin I; Pines M
Ann Surg; 1998 Apr; 227(4):575-82. PubMed ID: 9563549
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone.
Levi-Schaffer F; Nagler A; Slavin S; Knopov V; Pines M
J Invest Dermatol; 1996 Jan; 106(1):84-8. PubMed ID: 8592087
[TBL] [Abstract][Full Text] [Related]
8. The effect of halofuginone, an inhibitor of collagen type i synthesis, on urethral stricture formation: in vivo and in vitro study in a rat model.
Nagler A; Gofrit O; Ohana M; Pode D; Genina O; Pines M
J Urol; 2000 Nov; 164(5):1776-80. PubMed ID: 11025768
[TBL] [Abstract][Full Text] [Related]
9. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats.
Bruck R; Genina O; Aeed H; Alexiev R; Nagler A; Avni Y; Pines M
Hepatology; 2001 Feb; 33(2):379-86. PubMed ID: 11172339
[TBL] [Abstract][Full Text] [Related]
10. Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism.
McGaha TL; Kodera T; Spiera H; Stan AC; Pines M; Bona CA
Arthritis Rheum; 2002 Oct; 46(10):2748-61. PubMed ID: 12384935
[TBL] [Abstract][Full Text] [Related]
11. Halofuginone, an inhibitor of collagen type I synthesis, prevents postoperative adhesion formation in the rat uterine horn model.
Nagler A; Genina O; Lavelin I; Ohana M; Pines M
Am J Obstet Gynecol; 1999 Mar; 180(3 Pt 1):558-63. PubMed ID: 10076128
[TBL] [Abstract][Full Text] [Related]
12. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts.
McGaha TL; Phelps RG; Spiera H; Bona C
J Invest Dermatol; 2002 Mar; 118(3):461-70. PubMed ID: 11874485
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone.
Halevy O; Nagler A; Levi-Schaffer F; Genina O; Pines M
Biochem Pharmacol; 1996 Oct; 52(7):1057-63. PubMed ID: 8831725
[TBL] [Abstract][Full Text] [Related]
14. Halofuginone: an inhibitor of collagen type I synthesis.
Granot I; Halevy O; Hurwitz S; Pines M
Biochim Biophys Acta; 1993 Feb; 1156(2):107-12. PubMed ID: 8427869
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.
Elkin M; Ariel I; Miao HQ; Nagler A; Pines M; de-Groot N; Hochberg A; Vlodavsky I
Cancer Res; 1999 Aug; 59(16):4111-8. PubMed ID: 10463616
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of neovascularization and tumor growth, and facilitation of wound repair, by halofuginone, an inhibitor of collagen type I synthesis.
Abramovitch R; Dafni H; Neeman M; Nagler A; Pines M
Neoplasia; 1999 Oct; 1(4):321-9. PubMed ID: 10935487
[TBL] [Abstract][Full Text] [Related]
17. Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis.
Pines M; Knopov V; Genina O; Lavelin I; Nagler A
J Hepatol; 1997 Aug; 27(2):391-8. PubMed ID: 9288615
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of collagen synthesis, smooth muscle cell proliferation, and injury-induced intimal hyperplasia by halofuginone.
Nagler A; Miao HQ; Aingorn H; Pines M; Genina O; Vlodavsky I
Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):194-202. PubMed ID: 9012656
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the effect of halofuginone on bleomycin-induced scleroderma.
Yamamoto T; Nishioka K
Rheumatology (Oxford); 2002 May; 41(5):594-6. PubMed ID: 12011392
[No Abstract] [Full Text] [Related]
20. Halofuginone, an inhibitor of collagen synthesis by rat stellate cells, stimulates insulin-like growth factor binding protein-1 synthesis by hepatocytes.
Gnainsky Y; Spira G; Paizi M; Bruck R; Nagler A; Abu-Amara SN; Geiger B; Genina O; Monsonego-Ornan E; Pines M
J Hepatol; 2004 Feb; 40(2):269-77. PubMed ID: 14739098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]